Tenon Medical, Inc. (TNON)
NASDAQ:TNON
Earnings Data
Report Date
May 19, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.31Last Year’s EPS
-1.01Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented strong operational and commercial progress—record revenues, large quarter-over-quarter growth, meaningful gross margin improvement, FDA 510(k) clearance for SImmetry+, early clinical validation, expanded IP and follow-on financings to extend runway. These positives were tempered by a significant year-over-year decline in cash, continued large net losses and an operating expense base that remains several times revenue, meaning continued execution and successful commercialization will be critical. The company has taken steps to mitigate liquidity risk via financings and expects continued momentum into 2026, but material execution and burn-rate risks remain.Company Guidance
Record Annual and Quarterly Revenue Growth
Full year revenue of $3.9M, a 20% increase vs. 2024; Q4 revenue of $1.5M, a 92% increase vs. Q4 2024 ($0.8M), reflecting strong second-half momentum and new physician adoption.
Substantial Gross Profit and Margin Improvement
Q4 gross profit of $1.0M (69% gross margin) vs. $0.4M (46%) prior-year quarter — a 188% increase in gross profit and a 23 percentage-point margin improvement. FY gross profit of $2.4M (60% margin), up 38% and +8 percentage points vs. prior year.
Regulatory Clearance and Commercial Rollout
Received FDA 510(k) clearance for the next-generation SImmetry+ SI-Joint Fusion System and completed early clinical cases in Q4, supporting initial commercial rollout and physician validation.
Strengthened Financial Position via Financings
Completed a $2.85M At-The-Market PIPE during the quarter and, subsequent to quarter-end, closed a $4.3M private placement of senior convertible notes — providing additional runway to fund commercial expansion and clinical programs.
Operational Efficiency and Cost of Sales Reduction
Management reported reductions in cost of sales and improved operational efficiencies leading to better field productivity and absorption of fixed costs, contributing materially to gross margin expansion.
Commercial and Clinical Engagement Metrics
Hosted 24 physicians and targeted training sessions in Q4 alone; management reported record metrics across users and surgeries and expressed strong physician enthusiasm for the expanded portfolio.
Intellectual Property Expansion
Notices of allowance received for multiple patent applications; global estate now includes 29 issued U.S. patents, 9 international patents and 31 pending applications, enhancing platform defensibility.
TNON Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
TNON Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 19, 2026 | $0.83 | $0.80 | -3.95% |
Nov 13, 2025 | $1.18 | $1.18 | 0.00% |
Aug 13, 2025 | $1.67 | $1.40 | -16.17% |
May 13, 2025 | $1.24 | $1.11 | -10.48% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Tenon Medical, Inc. (TNON) report earnings?
Tenon Medical, Inc. (TNON) is schdueled to report earning on May 19, 2026, After Close (Confirmed).
What is Tenon Medical, Inc. (TNON) earnings time?
Tenon Medical, Inc. (TNON) earnings time is at May 19, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TNON EPS forecast?
TNON EPS forecast for the fiscal quarter 2026 (Q1) is -0.31.